The biotech has nominated MB-111, a drug it's developing as a treatment for elevated triglycerides, as its first clinical development candidate.

From STAT’s Adam Feuerstein: The FDA informed Capricor Therapeutics that a meeting of outside experts will be convened to ...

CRISPR Therapeutics and Intellia face 2025 volatility, but CRSP’s strong cash and launches make it more attractive than NTLA.

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...

The popular growth investor keeps adding to some of her favorite stocks.

Another notable trade was the sale of 67,053 shares of Schrödinger Inc (NASDAQ: SDGR) by the ARKG ETF, valued at $1,726,614.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication ...

Cathie Wood's ARK Invest has increased its stake in a Chinese technology giant an equity favored by Michael Burry.